Quick Answer
ADC Therapeutics SA reported Diluted EPS of $1.12 per share (loss) for fiscal year 2025.
ADC Therapeutics SA Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.12 | +30.9% |
| 2024 | -$1.62 | +44.9% |
| 2023 | -$2.94 | -46.3% |
| 2022 | -$2.01 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | +28.6% | +40.0% |
| June 30, 2025 | -$0.50 | -31.6% | -38.9% |
| March 31, 2025 | -$0.36 | +35.7% | +14.3% |
| September 30, 2024 | -$0.42 | +26.3% | -10.5% |
| June 30, 2024 | -$0.38 | +36.7% | +32.1% |
| March 31, 2024 | -$0.56 | +23.3% | +1.8% |
| September 30, 2023 | -$0.57 | — | +5.0% |
| June 30, 2023 | -$0.60 | — | +17.8% |
- ADC Therapeutics SA showed an increase of +30.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, ADC Therapeutics SA’s diluted eps has grown by 44.3% (from $2.01 per share (loss) to $1.12 per share (loss)).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: